RxDoctor Payments Data

Alexander Barash

Ophthalmology · New York, NYNPI 1891052338

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (43.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Alimera Sciences, Inc. at 35.8% of the total. Reporting peaked in 2019 at $5,972 and has fallen 91.4% since, to $515 in 2025. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,795in general payments, 2019–2025

Across 46 payments — averaging $321.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alimera Sciences, Inc.$5K
  • Novartis$3K
  • AbbVie$3K
  • Alcon$778
  • Bausch & Lomb Americas Inc.$616
  • Regeneron Healthcare Solutions, Inc.$248
  • plus $1K from 10 others

What the payments were for

  • Consulting fees$6,44944%
  • Speaking & faculty fees$5,00034%
  • Travel & lodging$3602%
  • Food & beverage$2,98720%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,795 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York →

Medicare billing

Part B allowed, 2024
$362,162
Medicare patients
302
Services billed
3,530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate41$1,215
Brimonidine Tartrate17$433
Ketorolac Tromethamine15$222
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat17$206
Latanoprost14$140
Ofloxacin11$138

Paid to pharmacies, not to this prescriber.

Other ophthalmology in New York

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →